Zacks: Analysts Expect Stealth BioTherapeutics Corp (MITO) Will Post Earnings of -$0.26 Per Share

Equities analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will report earnings of ($0.26) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. The business is scheduled to report its next earnings results on Thursday, July 4th.

On average, analysts expect that Stealth BioTherapeutics will report full year earnings of ($1.11) per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.08) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Stealth BioTherapeutics.

MITO has been the subject of a number of recent research reports. BMO Capital Markets initiated coverage on shares of Stealth BioTherapeutics in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $29.00 target price for the company. Evercore ISI assumed coverage on shares of Stealth BioTherapeutics in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $35.00 target price for the company. Nomura assumed coverage on Stealth BioTherapeutics in a research note on Tuesday, March 12th. They issued a “buy” rating and a $23.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Stealth BioTherapeutics in a research note on Tuesday, March 12th. They issued a “hold” rating and a $16.00 price target for the company.

Shares of Stealth BioTherapeutics stock traded down $0.40 during trading on Tuesday, reaching $12.70. The company’s stock had a trading volume of 7,347 shares, compared to its average volume of 11,253. Stealth BioTherapeutics has a 52 week low of $11.11 and a 52 week high of $20.99.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

See Also: Why are percentage gainers important?

Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.